PL2945642T3 - Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom - Google Patents

Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom

Info

Publication number
PL2945642T3
PL2945642T3 PL14700872.6T PL14700872T PL2945642T3 PL 2945642 T3 PL2945642 T3 PL 2945642T3 PL 14700872 T PL14700872 T PL 14700872T PL 2945642 T3 PL2945642 T3 PL 2945642T3
Authority
PL
Poland
Prior art keywords
protein
treating
factor
preventing diseases
diseases
Prior art date
Application number
PL14700872.6T
Other languages
English (en)
Inventor
Kai Christoph Wollert
Mortimer KORF-KLINGEBIEL
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Publication of PL2945642T3 publication Critical patent/PL2945642T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
PL14700872.6T 2013-01-17 2014-01-16 Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom PL2945642T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151593 2013-01-17
PCT/EP2014/050788 WO2014111458A2 (en) 2013-01-17 2014-01-16 Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases

Publications (1)

Publication Number Publication Date
PL2945642T3 true PL2945642T3 (pl) 2024-07-29

Family

ID=47559322

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14700872.6T PL2945642T3 (pl) 2013-01-17 2014-01-16 Białko czynnika 1 do zastosowania w leczeniu lub zapobieganiu chorobom

Country Status (16)

Country Link
US (1) US10369198B2 (pl)
EP (2) EP2945642B1 (pl)
JP (4) JP6809789B2 (pl)
CN (6) CN104968361B (pl)
CA (1) CA2898128A1 (pl)
DK (1) DK2945642T3 (pl)
ES (1) ES2986021T3 (pl)
FI (1) FI2945642T3 (pl)
HR (1) HRP20240623T1 (pl)
HU (1) HUE068364T2 (pl)
LT (1) LT2945642T (pl)
PL (1) PL2945642T3 (pl)
PT (1) PT2945642T (pl)
RS (1) RS65553B1 (pl)
SI (1) SI2945642T1 (pl)
WO (1) WO2014111458A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2945642T (pt) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Proteína do fator 1 para utilização no tratamento ou prevenção de doenças
CN105934249A (zh) 2013-11-21 2016-09-07 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
WO2016019368A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10435757B1 (en) 2016-06-15 2019-10-08 University Of South Florida Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof
CN108802372B (zh) * 2018-06-19 2021-05-11 上海伦泽生物科技有限公司 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒
EP4087489B1 (en) 2020-01-08 2025-05-14 Vitruvia Holdings Inc. Methods and computing system for processing ultrasound image to determine health of subdermal tissue
MX2022008727A (es) * 2020-01-21 2022-10-07 Boehringer Ingelheim Int Factor de crecimiento derivado de mieloide para su uso en el tratamiento o la prevencion de fibrosis, hipertrofia o insuficiencia cardiaca.
CN114149498B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
CN114149499B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用
CN114149500B (zh) * 2020-09-07 2023-12-01 复旦大学附属华山医院 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用
US20250325704A1 (en) 2020-12-23 2025-10-23 Boehringer Ingelheim International Gmbh Viral capsid proteins with specificity to heart tissue cells
JP2024523707A (ja) * 2021-07-08 2024-06-28 テナヤ セラピューティクス， インコーポレイテッド 遺伝子治療のための最適化された発現カセット
JP2025518285A (ja) 2022-06-03 2025-06-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄由来増殖因子の組換え発現
TW202426036A (zh) 2022-09-08 2024-07-01 德商百靈佳殷格翰國際有限公司 用於治療心因性休克的骨髓衍生性生長因子（二）
WO2025047991A1 (en) 2023-09-01 2025-03-06 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing a liver disorder
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2025120204A1 (en) 2023-12-06 2025-06-12 Boehringer Ingelheim International Gmbh Novel formulation comprising myeloid-derived growth factor
CN120738287B (zh) * 2025-07-03 2026-02-24 广州医科大学附属妇女儿童医疗中心 急性低灌注动物模型的构建方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
AU717542B2 (en) 1996-06-11 2000-03-30 Merck & Co., Inc. Synthetic hepatitis C genes
JP2001506484A (ja) * 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ
CA2265923A1 (en) 1996-09-13 1998-03-19 Sagami Chemical Research Center Human proteins having secretory signal sequences and dnas encoding these proteins
WO2002008284A2 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
HUP0001964A3 (en) * 1997-01-29 2002-01-28 Cornell Res Foundation Inc Ith Multiple site delivery of adenoviral vector for the induction of angiogenesis
AU4761100A (en) 1999-05-26 2000-12-18 Kalle Saksela Methods and materials for generating sh3 domains with tailored binding properties
DK1212417T3 (da) * 1999-06-02 2008-09-01 Genentech Inc Fremmelse eller inhibering af angiogenese og vaskularisering
CA2381985A1 (en) * 1999-08-16 2001-02-22 Universita'degli Studi Di Siena Vegf-d and angiogenic use thereof
WO2002081681A1 (fr) * 2001-03-30 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Nouvelle utilisation de la cytokine sf20
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
US7452968B2 (en) * 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US8486438B2 (en) 2004-01-29 2013-07-16 Brown University Methods for progenitor cell recruitment and isolation
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US20080004232A1 (en) * 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2130547A1 (en) * 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
MX336152B (es) * 2009-08-29 2016-01-08 Abbvie Inc Proteinas terapeutico de union a dll4.
WO2011094446A1 (en) * 2010-01-27 2011-08-04 Neumedicines, Inc A method for treating brain cancer using a novel tumor suppressor gene and secreted factor
KR20120095063A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 ＩＬ-27로 유도된 ｐ53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
PT2945642T (pt) * 2013-01-17 2024-05-27 Medizinische Hochschule Hannover Proteína do fator 1 para utilização no tratamento ou prevenção de doenças

Also Published As

Publication number Publication date
CN111100197B (zh) 2024-11-15
SI2945642T1 (sl) 2024-07-31
JP6809789B2 (ja) 2021-01-06
CN110894226A (zh) 2020-03-20
CN104968361A (zh) 2015-10-07
RS65553B1 (sr) 2024-06-28
US20150352186A1 (en) 2015-12-10
WO2014111458A3 (en) 2014-09-12
PT2945642T (pt) 2024-05-27
JP2020203894A (ja) 2020-12-24
CA2898128A1 (en) 2014-07-24
FI2945642T3 (fi) 2024-05-10
HK1215540A1 (en) 2016-09-02
WO2014111458A2 (en) 2014-07-24
CN110922468A (zh) 2020-03-27
JP2023025005A (ja) 2023-02-21
CN110922468B (zh) 2024-09-24
CN104968361B (zh) 2019-12-17
ES2986021T3 (es) 2024-11-08
JP2016506911A (ja) 2016-03-07
CN110922467A (zh) 2020-03-27
DK2945642T3 (da) 2024-05-27
EP3747457A3 (en) 2021-03-03
HUE068364T2 (hu) 2024-12-28
JP2025143268A (ja) 2025-10-01
EP2945642A2 (en) 2015-11-25
HRP20240623T1 (hr) 2024-08-02
LT2945642T (lt) 2024-06-25
EP2945642B1 (en) 2024-02-21
US10369198B2 (en) 2019-08-06
JP7685737B2 (ja) 2025-05-30
CN110903378A (zh) 2020-03-24
EP3747457A2 (en) 2020-12-09
CN111100197A (zh) 2020-05-05

Similar Documents

Publication Publication Date Title
HUE068364T2 (hu) Faktor 1 fehérje betegségek kézélésében vagy megelõzésében váló alkalmazásra
SG11202012656WA (en) Heterocyclic compounds useful in the treatment of disease
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PT3060237T (pt) Proteína de reprogramação modificada para utilização no tratamento de um cancro
SG11201509012QA (en) Sobetirome in the treatment of myelination diseases
ZA201601430B (en) Insecticidal proteins and methods for their use
PL3010506T3 (pl) Pridopidyna w leczeniu choroby huntingtona
ZA201509369B (en) Insecticidal proteins and methods for their use
HUE039560T2 (hu) Mikro méretû zárófedés és kapcsolódó eljárások bõr kezelésére
SI4374873T1 (sl) Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
IL242770B (en) A therapeutic combination that includes oxazolidinone-quinolones for use in the treatment of bacterial infections
GB201511382D0 (en) Novel compounds and their use in therapy
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
PL3044229T3 (pl) Peptydy do zastosowania w leczeniu zapalenia błony śluzowej jamy ustnej
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
GB201308753D0 (en) Compounds and their use in therapy
SG10201705592YA (en) Protein slurp-1 for use in the treatment of ocular diseases
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
EP3085710A4 (en) Protein and use thereof in treating multiple sclerosis
GB201308217D0 (en) Compounds and their use in therapy
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
ZA201302565B (en) Methods for treating hyperuricemia and related diseases